Charles River Laboratories International, Inc.
CRL
$162.85
-$5.84-3.46%
NYSE
| 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.03B | 4.02B | 4.02B | 4.03B | 4.02B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.03B | 4.02B | 4.02B | 4.03B | 4.02B |
| Cost of Revenue | 2.64B | 2.61B | 2.63B | 2.62B | 2.63B |
| Gross Profit | 1.39B | 1.40B | 1.40B | 1.41B | 1.40B |
| SG&A Expenses | 700.61M | 727.81M | 729.02M | 742.69M | 722.72M |
| Depreciation & Amortization | 160.45M | 174.87M | 124.08M | 129.07M | 132.16M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.50B | 3.51B | 3.48B | 3.49B | 3.48B |
| Operating Income | 526.53M | 501.96M | 542.35M | 539.32M | 540.39M |
| Income Before Tax | -165.42M | -99.50M | -22.20M | -18.15M | 30.08M |
| Income Tax Expenses | 17.42M | 42.66M | 57.43M | 46.73M | 53.39M |
| Earnings from Continuing Operations | -182.84 | -142.16 | -79.62 | -64.88 | -23.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.81M | -2.18M | -2.66M | -2.16M | -1.98M |
| Net Income | -184.65M | -144.34M | -82.28M | -67.04M | -25.29M |
| EBIT | 526.53M | 501.96M | 542.35M | 539.32M | 540.39M |
| EBITDA | 887.62M | 874.57M | 855.19M | 926.19M | 858.34M |
| EPS Basic | -3.75 | -2.95 | -1.55 | -1.31 | -0.63 |
| Normalized Basic EPS | 3.67 | 4.73 | 4.78 | 4.95 | 4.84 |
| EPS Diluted | -3.76 | -2.96 | -1.56 | -1.33 | -0.65 |
| Normalized Diluted EPS | 3.66 | 4.71 | 4.77 | 4.93 | 4.82 |
| Average Basic Shares Outstanding | 196.53M | 198.26M | 200.18M | 202.36M | 204.76M |
| Average Diluted Shares Outstanding | 196.91M | 198.81M | 200.73M | 202.89M | 205.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |